Regeneron's blockbuster eye drug posts weaker sales due to inventory impact

U.S. drugmaker Regeneron Pharmaceuticals Inc (REGN.O) missed Wall Street estimates for quarterly profit on Thursday, hurt by softer sales of its blockbuster eye drug Eylea due to reduction in wholesaler inventory.